Prednisone remains both lifeline and liability. New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict. @RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p